Key Highlights

  • DRI Healthcare Trust — TSX:DHT.U gained 4.96% on September 21, 2026.
  • The move came on the same day the company announced a proposed US$316 million purchase of Royalty participation rights on tavapadon.
  • Tavapadon is an investigational oral treatment for Parkinson’s disease that has been submitted to the U.S. FDA.
  • DRI Healthcare would receive tiered royalties ranging from mid-single-digit to low-double-digit rates on annual U.S. net sales if the transaction closes.
  • The agreement also includes four annual fixed payments of US$23.4 million following FDA approval, plus certain sales milestones.
  • DRI Healthcare declared a US$0.11-per-unit quarterly distribution for Q3 2026, payable October 20 to unitholders of record September 30.

Why Is DRI Healthcare Stock in Focus Today?

DRI Healthcare stock rose 4.96% on September 21, 2026, with the latest move coinciding directly with a significant new royalty Acquisition announcement.

The company announced that it had entered into purchase agreements with funds managed by Bain Capital and NovaQuest Capital Management to acquire royalty participation rights on U.S. net sales of tavapadon for an aggregate purchase price of US$316 million. The transaction is conditional on FDA approval of tavapadon and other customary closing conditions.

This is a particularly relevant development for DRI because the company's Business model is built around acquiring royalty streams from pharmaceutical products and converting future drug sales into long-duration cash flows.

What Is Tavapadon and Why Does It Matter to DHT.U?

Tavapadon is an investigational dopamine D1/D5 receptor partial agonist being developed as a once-daily oral treatment for Parkinson's disease.

The drug has been submitted to the FDA for approval, with approval expected in the third quarter of 2026 according to DRI's September 21 announcement. The proposed royalty transaction therefore represents exposure to a potentially commercial-stage pharmaceutical asset while its regulatory decision remains an important condition for closing.

For DHT.U, the transaction provides another potential royalty stream tied to a large therapeutic area and adds a new asset to its diversified pharmaceutical royalty portfolio.

How Could the US$316 Million Tavapadon Deal Generate Revenue?

Under the proposed agreement, DRI Healthcare would receive tiered royalties on annual U.S. net sales of tavapadon, with rates ranging from the mid-single digits to low double digits.

The company would also be entitled to certain sales milestone payments when cumulative U.S. net sales reach specified thresholds.

In addition, DRI would receive four annual fixed payments of US$23.4 million on the first four anniversaries of FDA approval.

This structure means the Economics would combine recurring royalties with fixed payments and potential sales milestones, subject to regulatory approval and eventual commercial performance.

What Does DRI Healthcare's Existing Portfolio Look Like?

DRI Healthcare already operates a diversified portfolio of pharmaceutical royalty interests.

At June 30, 2026, its portfolio included 28 royalty streams covering 22 products across therapeutic areas including oncology, neurology, ophthalmology, endocrinology, hematology, dermatology, lysosomal storage disorders and immunology.

During Q2 2026, the portfolio generated approximately US$46.5 million of total cash royalty receipts, while first-half 2026 cash royalty receipts reached approximately US$104.8 million.

The tavapadon transaction would add another potential royalty stream to this portfolio, subject to the transaction's closing conditions.

How Did DRI Healthcare Perform in the First Half of 2026?

DRI Healthcare reported US$48.2 million of royalty income in Q2 2026 and approximately US$94.8 million for the first six months of 2026.

At June 30, the company had approximately US$55.2 million in cash and cash equivalents and approximately US$372.3 million of long-term debt, including senior notes, convertible debentures, preferred securities and the long-term portion of its Credit facility.

The financial position is relevant because large royalty acquisitions require substantial capital, making financing structure and future royalty receipts important considerations.

Why Is the EKTERLY Transaction Also Relevant?

DRI Healthcare recently received approximately US$178 million from the exercise of its contractual Put Option relating to its EKTERLY royalty participation right.

The transaction was triggered following Chiesi Group's acquisition of KalVista Pharmaceuticals. DRI announced receipt of the put price on August 11, completing the transaction and terminating its royalty participation in EKTERLY.

The proceeds provided additional capital that can be redeployed into new royalty opportunities, including the proposed tavapadon transaction.

What Is DRI Healthcare's Dividend and Distribution Position?

DRI Healthcare declared a quarterly distribution of US$0.11 per unit for Q3 2026, payable October 20, 2026, to unitholders of record on September 30.

The quarterly distribution is an important part of the DHT.U Investment structure because the trust seeks to return capital to unitholders while continuing to acquire additional pharmaceutical royalty assets.

Future distributions will remain dependent on the trust's cash generation, portfolio performance, financing requirements and capital-allocation decisions.

What Drove the 4.96% Gain on September 21, 2026?

The 4.96% gain on September 21 occurred on the same day as the announcement of the US$316 million tavapadon royalty acquisition.

That makes the transaction a direct piece of company-specific news surrounding the session. However, the final economic impact depends on FDA approval, completion of the transaction and eventual commercial performance of tavapadon.

The proposed acquisition therefore adds a significant new catalyst to DHT.U while also increasing the company's exposure to the neurology and Parkinson's disease treatment market.

What Should Investors Watch Next for TSX:DHT.U?

The most immediate developments include the FDA decision for tavapadon and satisfaction of the conditions required to close the US$316 million royalty transaction.

Investors may also monitor the four scheduled US$23.4 million fixed payments, potential sales milestones, royalty receipts from the existing portfolio, future royalty acquisitions and the October 20 quarterly distribution.

DRI's ability to continue recycling capital into new pharmaceutical royalty streams will also remain important as the trust expands its portfolio.

The 4.96% rise on September 21, 2026 therefore comes alongside a major new transaction that could add a potentially long-duration Parkinson's disease royalty stream to DRI Healthcare's existing portfolio.